Abstract
We report safety, tolerability, and 12-week sustained virologic response with half-standard dose sofosbuvir and standard-dose simeprevir combination therapy in a hepatitis C virus genotype 1a-infected liver transplant recipient on hemodialysis - uncharted territory for sofosbuvir-based therapy. The patient was a non-responder to prior treatment with pegylated interferon plus ribavirin. Sofosbuvir efficacy was maintained despite pill-splitting and administration of half-standard dose, 200 mg per day. No drug-drug interactions were noted with tacrolimus-based immunosuppression. Laboratory tests remained stable or improved during therapy. Our observation, if reproduced in a larger study, may lead to significant improvement in clinical outcomes and cost savings in this patient population.
Original language | English (US) |
---|---|
Pages (from-to) | 275-278 |
Number of pages | 4 |
Journal | Transplant Infectious Disease |
Volume | 17 |
Issue number | 2 |
DOIs | |
State | Published - Apr 1 2015 |
Keywords
- Direct-acting antivirals
- Hemodialysis
- Hepatitis C virus
- Liver transplantation
- Simeprevir
- Sofosbuvir
ASJC Scopus subject areas
- Infectious Diseases
- Transplantation